Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left
Molecular Biosystems of San Diego plans to begin phase-III clinicaltrials for its FS069 second-generation ultrasound contrast agent.MBI said this month that 200 patients undergoing echocardiographywill be studied for the agent's ability to provide left ventricularopacification and to enhance endocardial border delineation. MBIdeveloped Albunex, which is marketed in the U.S. by MallinckrodtMedical. Mallinckrodt also has marketing rights to FS069 (SCAN9/13/95).
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.